美沙拉秦对缓解期溃疡性结肠炎患者血清炎症因子的影响

Effect of Mesalazine on the Serum Inflammatory Factors of Patients with Ulcerative Colitis in Remission

目的:探讨美沙拉秦对缓解期溃疡性结肠炎(UC)患者血清炎性因子水平的影响。方法:收集2013年5月至2016年5月于我院治疗的缓解期UC患者153例,随机分为观察组75例及对照组78例。对照组患者给予常规治疗,观察组在对照组的基础上加用美沙拉秦治疗。观察比较两组治疗前后的血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)、白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)水平、疾病活动指数(DAI)评分、临床疗效、病情复发和不良反应的发生情况。结果:治疗后,观察组治疗总有效率为96.0%,明显高于对照组的62.8%(P<0.05);观察组的血清IL-6、IL-8、IL-17及TNF-α水平均较治疗前明显降低,且显著低于对照组(P<0.05);两组的DAI评分均有明显改善,但观察组的改善幅度明显大于对照组(P<0.05);观察组患者的复发率(2.6%)显著低于对照组(21.8%)(P<0.05),两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:美沙拉秦治疗缓解期溃疡性结肠炎的临床疗效显著,可显著抑制患者的炎症反应,同时可改善患者的临床症状,降低复发率,且安全性高。

Objective： To investigate the effect of mesalazine on the serum inflammatory factors of patients with ulcerative colitis in remission. Methods： 153 patients with ulcerative colitis in remission admitted into our hospital were divided into the control group and the observation group. 78 cases in the control group were treated with conventional treatment, and 75 cases in the observation group were treated with mesalazine based on the control group. The serum inflammatory factors including IL-6, IL-8, IL-17, TNF-α, DAI score, clinical efficacy, relapse and adverse reaction in both groups were observed and compared. Results： After treatment, the clinical effective rate of observation group was 96.0%, which was much higher than that of the control group （62.8%, P〈0.05）. The serum levels of IL-6, IL-8, IL-17, TNF-α of both group were markedly lower than those before treatment, which were much lower in the observation group than those of the control group （P〈0.05）. The DAI score in both groups showed obvious improvement, and the DAI score of observation group was much better than that of the control group （P〈0.05）. In addition, the incidence of relapse was 2.6% in the observation group, which was significantly lower than that of the control group （21.8%, P〈0.05）, and there was no significant difference in the incidence of adverse reactions between the two groups （P 〉0.05）. Conclusion： Mesalazine had a great capability of treating patients with ulcerative colitis in remission by inhibiting the serum levels of inflammatory factors, improving the clinical symptoms and decreasing incidence of relapse with high safety.